Effort to boost effectiveness of antibiotics receives investment
Synereca Pharmaceuticals develops novel compounds that show promise in enhancing the effectiveness of existing antibiotics against drug-resistant bacteria that cause hundreds of thousands of hospital-acquired infections each year.Published: Wednesday, August 5, 2015 By: Staff Reports
i2E Inc. and Accele Venture Partners recently closed a $600,000 follow-on investment in Synereca Pharmaceuticals, a portfolio company of Accele Biopharma, an Oklahoma City-based biotechnology accelerator.
With the most recent investment, Synereca has received $2.5 million in funding to support its development of compounds that address the growing problem of bacterial resistance to current antibiotics.
Synereca’s lead program is designed to restore or increase the effectiveness of existing antibiotics that have been compromised by drug-resistant bacteria.